EyeGate Pharmaceuticals (EYEG)

Last close As at 27/03/2024

0.00 (0.00%)

Market capitalisation

Latest Insights

Financials

EyeGate recently delivered positive top-line data in a 20-patient trial studying the firm’s lead product, Ocular Bandage Gel (OBG), in patients with moderate dry eye disease (DED). Compared to the positive control, Allergan’s Refresh Preservative-Free OTC lubricant, OBG eye drops showed improvements in central corneal region staining, high order ocular aberrations (HOA) and best corrected visual acuity (BCVA). These results are indicative of therapeutic benefits and EyeGate is gearing to potentially launch a pivotal trial programme in H220.

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free